Breaking Finance News

Mirna Therapeutics Inc (NASDAQ:MIRN) has been downgraded to Market Perform in a report by Oppenheimer Holdings Inc. earlier today.

Showing a price of $2.47, Mirna Therapeutics Inc (NASDAQ:MIRN) traded 3.06% higher on the day. With the last stock price close down -50.35% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. The company has recorded a 50-day moving average of $2.98 and a two hundred day average of $4.07. Trade Volume was up over the average, with 61,560 shares of MIRN changing hands over the typical 28,677

Oppenheimer Holdings Inc. has downgraded Mirna Therapeutics Inc (NASDAQ:MIRN) to Market Perform in a statement released on 9/21/2016.

On 9/12/2016, HC Wainwright released a statement on Mirna Therapeutics Inc (NASDAQ:MIRN) raised the target price from $0.00 to $6.00 that suggested an upside of 1.35%.

Performance Chart

Mirna Therapeutics Inc (NASDAQ:MIRN)

Mirna Therapeutics Inc has 52 week low of $1.82 and a one year high of $11.01 and has a total market value of $0.

A total of 4 firms have reported on the stock. 3 brokerages rating the stock a strong buy, one broker rating the stock a buy, zero equity analysts rating the company a hold, 0 analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a 12-month price target of $11.00.

General Information About Mirna Therapeutics Inc (NASDAQ:MIRN)

Mirna Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response. This approach is known as microRNA replacement therapy. Its lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34) encapsulated in a liposomal nanoparticle formulation, has demonstrated clinical proof of concept as a single agent in its ongoing Phase I clinical trial. The Company's RNA molecules function as natural microRNAs when they enter human cells. These RNA molecules, which it calls microRNA mimics, may be used to replace those tumor suppressor microRNAs that are lost, or under expressed, in cancer cells. Its other preclinical product candidates include miR-215, miR-101, miR-16 and let-7.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *